Current Report Filing (8-k)
April 13 2020 - 8:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2020
89bio, Inc.
(Exact name
of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-39122
|
|
36-4946844
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
142 Sansome Street, Second Floor
San Francisco, CA 94104
(Address of principal executive offices, including zip code)
(415) 500-4614
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
ETNB
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On April 13, 2020, the Company issued a press release announcing that it closed enrollment in its Phase 1b/2a trial for nonalcoholic steatohepatitis with
98% of patients enrolled and has delayed initiation of its severe hypertriglyceridemia trial due to the ongoing COVID-19 pandemic. The press release also reported new preclinical data confirming BIO89-100s mechanism of action via potent FGF receptor agonism. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
On April 13, 2020, the Company also made available an updated corporate presentation on the Companys website. A copy of the corporate presentation
is furnished herewith as Exhibit 99.2 and incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 8.01, including Exhibits 99.1 and 99.2, shall not be deemed to be filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of
that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
89bio, Inc.
|
|
|
|
|
Date: April 13, 2020
|
|
|
|
By:
|
|
/s/ Rohan Palekar
|
|
|
|
|
|
|
Rohan Palekar
|
|
|
|
|
|
|
Chief Executive Officer
|
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2024 to May 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From May 2023 to May 2024